88,490 Shares in Johnson & Johnson (NYSE:JNJ) Bought by Arvest Bank Trust Division

Arvest Bank Trust Division bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 88,490 shares of the company's stock, valued at approximately $14,341,000.

Other large investors have also added to or reduced their stakes in the company. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after purchasing an additional 91 shares during the last quarter. Finally, Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $40,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 16th. Morgan Stanley boosted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $174.73.

Johnson & Johnson Stock Down 0.3 %

JNJ stock traded down $0.41 during midday trading on Thursday, reaching $146.23. The company had a trading volume of 6,174,458 shares, compared to its average volume of 7,118,662. The company has a 50 day moving average of $157.29 and a two-hundred day moving average of $156.35. The company has a market capitalization of $352.07 billion, a P/E ratio of 21.28, a PEG ratio of 2.66 and a beta of 0.51. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm's revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.66 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.